US Bancorp
FULC icon

US Bancorp’s Fulcrum Therapeutics FULC Stock Holding History

US Bancorp’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26
Closed -$199 – 4232
2026
Q1 		$199 Buy
+26
New +$241 ﹤0.01% 4101
2025
Q3 		– Sell
-1,911
Closed -$13.1K – 4115
2025
Q2 		$13.1K Sell
1,911
-189
-9% -$1.01K ﹤0.01% 3331
2025
Q1 		$6.05K Buy
+2,100
New +$7.71K ﹤0.01% 3601
2023
Q1 		– Sell
-153
Closed -$1.11K – 4133
2022
Q4 		$1.11K Sell
153
-1,960
-93% -$12.8K ﹤0.01% 3905
2022
Q3 		$17K Buy
+2,113
New +$15.1K ﹤0.01% 3104
2022
Q2 		– Sell
-790
Closed -$19K – 4123
2022
Q1 		$19K Buy
+790
New +$11.2K ﹤0.01% 3100

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

US Bancorp's FULC Position: Q2 2026 in Review

US Bancorp sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 26 shares — an estimated $199 sold.

US Bancorp first reported a position in FULC in Q1 2022 and held it in 6 quarters. The position peaked at $19K in Q1 2022. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • US Bancorp reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • US Bancorp sold 26 Fulcrum Therapeutics shares in Q2 2026, an estimated $199.
  • US Bancorp first reported a position in Fulcrum Therapeutics in Q1 2022 and held it in 6 quarters.
  • US Bancorp's Fulcrum Therapeutics position peaked at $19K in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.